Sunshine Biopharma (SBFM) Income towards Parent Company (2011 - 2026)

Sunshine Biopharma has reported Income towards Parent Company for 14 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 5.43% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$6.0 million (down 513.49% YoY), and the FY2025 full-year result was -$6.0 million, down 540.47% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$1.2 million, up from -$2.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was $4.3 million in Q4 2024, with the low at -$23.5 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$2.2 million across 5 years, with a median of -$1.2 million in 2022.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 3624.47% — and 2024, when it surged 446.59%.
• Sunshine Biopharma's Income towards Parent Company stood at -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then surged by 446.59% to $4.3 million in 2024, then plunged by 149.42% to -$2.1 million in 2025, then jumped by 41.9% to -$1.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$1.2 million (Q1 2026), -$2.1 million (Q4 2025), and -$883820.0 (Q3 2025), per Business Quant data.